335 Results

People

  1. Pastores
    Pastores
  2. Brennan
    Brennan
  3. Sepkowitz
    Sepkowitz
  4. Horwitz
    Horwitz
  5. Dunkel
    Dunkel
  6. Heller
    Heller
  7. Herr
    Herr
  8. Kelsen
    Kelsen
  9. Zelenetz
    Zelenetz
  10. Abou-Alfa
    Abou-Alfa

Groups

  1. Department of Medicine (168)
  2. Hematologic Malignancies, Division of (78)
  3. Center for Hematologic Malignancies (74)
  4. Solid Tumor Oncology Division (74)
  5. Surgery (69)
  6. Survivorship Research (47)
  7. Anesthesiology and Critical Care Medicine (30)
  8. Adult Leukemia (28)
  9. Center for Pancreatic Cancer Research (28)
  10. Division of Subspecialty Medicine (27)
  1. "sepsis"
Formats
  1. Journal Article (305)
  2. Review (13)
  3. Editorial (5)
  4. Research Letter (4)
  5. Conference Paper (3)
  6. Correspondence (3)
  7. Guidelines (2)
Groups
  1. Department of Medicine (168)
  2. Hematologic Malignancies, Division of (78)
  3. Center for Hematologic Malignancies (74)
  4. Solid Tumor Oncology Division (74)
  5. Surgery (69)
  6. Survivorship Research (47)

More Groups

People
  1. Stephen Pastores (22)
  2. Murray Brennan (11)
  3. Kent Sepkowitz (9)
  4. Martin Tallman (9)
  5. Steven Horwitz (8)
  6. Andrew Zelenetz (7)

More People

Years
  1. 2025 (19)
  2. 2024 (26)
  3. 2023 (19)
  4. 2022 (12)
  5. 2021 (7)
  6. 2020 (24)

More Years

Publications
  1. Journal of Clinical Oncology (22)
  2. Cancer (15)
  3. Lancet Oncology (13)
  4. Leukemia and Lymphoma (12)
  5. Blood (11)
  6. Journal of Urology (8)

More Publications

Publishers
  1. Elsevier Science, Inc. (36)
  2. Elsevier Inc. (33)
  3. American Society of Clinical Oncology (24)
  4. Wiley Blackwell (22)
  5. Lippincott Williams & Wilkins (19)
  6. Nature Publishing Group (18)

More Publishers

Results (335)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • First-line regorafenib with nivolumab and chemotherapy in advanced oesophageal, gastric, or gastro-oesophageal junction cancer in the USA: A single-arm, single-centre, phase 2 trial
    Journal Article

    Cytryn, S. L.; Moy, R. H.; Cowzer, D.; Shah, R. H.; Chou, J. F.; Joshi, S. S.; Ku, G. Y.; Maron, S. B.; Desai, A.; Yang, J.; more...
    Lancet Oncology (2023)

    Fulltext@MSK | Save
  • Feasibility assessment of a biomarker-guided kidney-sparing sepsis bundle: The limiting acute kidney injury progression in sepsis trial
    Journal Article

    Gómez, H.; Zarbock, A.; Pastores, S. M.; Frendl, G.; Bercker, S.; Asfar, P.; Conrad, S. A.; Creteur, J.; Miner, J.; Mira, J. P.; more...
    Critical Care Explorations (2023)

    Fulltext@MSK | Save
  • Brentuximab vedotin with AVD for stage II–IV HIV-related Hodgkin lymphoma (AMC 085): Phase 2 results from an open-label, single arm, multicentre phase 1/2 trial
    Journal Article

    Rubinstein, P. G.; Moore, P. C.; Bimali, M.; Lee, J. Y.; Rudek, M. A.; Chadburn, A.; Ratner, L.; Henry, D. H.; Cesarman, E.; DeMarco, C. E.; more...
    The Lancet Haematology (2023)

    Fulltext@MSK | Save
  • Entospletinib with decitabine in acute myeloid leukemia with mutant TP53 or complex karyotype: A phase 2 substudy of the Beat AML Master Trial
    Journal Article

    Duong, V. H.; Ruppert, A. S.; Mims, A. S.; Borate, U.; Stein, E. M.; Baer, M. R.; Stock, W.; Kovacsovics, T.; Blum, W.; Arellano, M. L.; more...
    Cancer (2023)

    Fulltext@MSK | Save
  • Delirium as a risk factor for mortality in critically ill patients with cancer
    Journal Article

    Tao, J.; Seier, K.; Marasigan-Stone, C. B.; Simondac, J. S. S.; Pascual, A. V.; Kostelecky, N. T.; SantaTeresa, E.; Nwogugu, S. O.; Yang, J. J.; Schmeltz, J.; more...
    JCO Oncology Practice (2023)

    Fulltext@MSK | Save
  • Pevonedistat with azacitidine in older patients with TP53-mutated AML: A phase 2 study with laboratory correlates
    Research Letter

    Saliba, A. N.; Kaufmann, S. H.; Stein, E. M.; Patel, P. A.; Baer, M. R.; Stock, W.; Deininger, M.; Blum, W.; Schiller, G. J.; Olin, R. L.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
    Journal Article

    de Botton, S.; Cluzeau, T.; Vigil, C.; Cook, R. J.; Rousselot, P.; Rizzieri, D. A.; Liesveld, J. L.; Fenaux, P.; Braun, T.; Banos, A.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Increasing rates of general anesthesia use in lumpectomy procedures: A 15-year trends analysis
    Journal Article

    Rubenstein, R. N.; Tadros, A.; Slutsky, H. L.; Plotsker, E. L.; Haglich, K.; Stern, C. S.; Morrow, M.; Nelson, J. A.; Nelson, P.
    Journal of Surgical Oncology (2023)

    Fulltext@MSK | Save
  • Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma
    Journal Article

    Roddie, C.; Lekakis, L. J.; Marzolini, M. A. V.; Ramakrishnan, A.; Zhang, Y.; Hu, Y.; Peddareddigari, V. G. R.; Khokhar, N.; Chen, R.; Basilico, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • How I treat unique and difficult-to-manage cases of CAR T-cell therapy–associated neurotoxicity
    Journal Article

    Santomasso, B. D.; Gust, J.; Perna, F.
    Blood (2023)

    Fulltext@MSK | Save